Skip to main content
Top

09-12-2023 | Non-Tuberculous Mycobacteria | Case Report

The successful treatment of microscopic polyangiitis associated with non-tuberculous mycobacterial-pulmonary disease

Authors: Ryuichi Yoshii, Kengo Kajiwara, Naomichi Uemura, Koki Matsushita, Tomohumi Nakamura, Masao Tomita, Masashi Mukoyama

Published in: CEN Case Reports

Login to get access

Abstract

While the incidence and prevalence of non-tuberculous mycobacterial-pulmonary disease (NTM-PD) are increasing and microscopic polyangiitis (MPA) is common in East Asian countries, case reports of MPA associated with NTM-PD are limited. A 72-year-old male receiving treatment for NTM-PD with antibiotics was referred to our hospital with fever and arthralgia that developed a few months previously. A blood test revealed the presence of the myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA) and renal impairment. Based on a pathological examination of renal tissue, which showed crescentic glomerulonephritis, the patient was diagnosed with MPA. Due to acute kidney injury and strongly positive MPO-ANCA, pulse steroid therapy was initiated followed by intravenous rituximab (RTX). The patient also received plasmapheresis (14 sessions). Renal dysfunction was reversed. MPA associated with NTM-PD is extremely rare and, thus, there is currently no established treatment. Our patient was diagnosed with MPA based on the findings of renal biopsy while receiving treatment for NTM-PD. RTX and plasmapheresis combined with systemic glucocorticoid therapy were initiated before these clinical conditions had fully recovered. Although MPA secondary to NTM-PD may be more refractory to treatment than primary MPA in the presence of a very low interferon-gamma (IFN-γ) level, this case was successfully treated with steroids, RTX, and plasmapheresis.
Literature
1.
go back to reference Bonaiti G, Pesci A, Marruchella A, Lapadula G, Gori A, Aliberti S. Nontuberculous mycobacteria in noncystic fibrosis bronchiectasis. Biomed Res Int. 2015;2015: 197950.CrossRefPubMedPubMedCentral Bonaiti G, Pesci A, Marruchella A, Lapadula G, Gori A, Aliberti S. Nontuberculous mycobacteria in noncystic fibrosis bronchiectasis. Biomed Res Int. 2015;2015: 197950.CrossRefPubMedPubMedCentral
2.
go back to reference Moore JE, Kruijshaar ME, Ormerod LP, Drobniewski F, Abubakar I. Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995–2006. BMC Public Health. 2010;10:612.CrossRefPubMedPubMedCentral Moore JE, Kruijshaar ME, Ormerod LP, Drobniewski F, Abubakar I. Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995–2006. BMC Public Health. 2010;10:612.CrossRefPubMedPubMedCentral
3.
go back to reference Watts RA, Scott DG, Jayne DR, Ito-Ihara T, Muso E, Fujimoto S, Harabuchi Y, Kobayashi S, Suzuki K, Hashimoto H. Renal vasculitis in Japan and the UK–are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant. 2008;23:3928–31.CrossRefPubMed Watts RA, Scott DG, Jayne DR, Ito-Ihara T, Muso E, Fujimoto S, Harabuchi Y, Kobayashi S, Suzuki K, Hashimoto H. Renal vasculitis in Japan and the UK–are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant. 2008;23:3928–31.CrossRefPubMed
4.
go back to reference Fisher E, Hayem G, Kaplan G, Le Hello C, Mouthon L, Larroche C, Lemaire V, Piette AM, Piette JC, Ponge T, Puechal X, Rossert J, Sarrot-Reynauld F, Sicard D, Ziza JM, Kahn MF, Guillevin L. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473–80.CrossRefPubMed Fisher E, Hayem G, Kaplan G, Le Hello C, Mouthon L, Larroche C, Lemaire V, Piette AM, Piette JC, Ponge T, Puechal X, Rossert J, Sarrot-Reynauld F, Sicard D, Ziza JM, Kahn MF, Guillevin L. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473–80.CrossRefPubMed
5.
go back to reference Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA. Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol. 1986;63:143–7.CrossRefPubMed Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA. Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol. 1986;63:143–7.CrossRefPubMed
6.
go back to reference Bynoe AG, Scott CS, Ford P, Roberts BE. Decreased T helper cells in the myelodysplastic syndromes. Br J Haematol. 1983;54:97–102.CrossRefPubMed Bynoe AG, Scott CS, Ford P, Roberts BE. Decreased T helper cells in the myelodysplastic syndromes. Br J Haematol. 1983;54:97–102.CrossRefPubMed
7.
go back to reference Kerndrup G, Meyer K, Ellegaard J, Hokland P. Natural killer (NK)-cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome. Leuk Res. 1984;8:239–47.CrossRefPubMed Kerndrup G, Meyer K, Ellegaard J, Hokland P. Natural killer (NK)-cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome. Leuk Res. 1984;8:239–47.CrossRefPubMed
8.
go back to reference Kuzmich PV, Ecker GA, Karsh J. Rheumatic manifestations in patients with myelodysplastic and myeloproliferative diseases. J Rheumatol. 1994;21:1649–54.PubMed Kuzmich PV, Ecker GA, Karsh J. Rheumatic manifestations in patients with myelodysplastic and myeloproliferative diseases. J Rheumatol. 1994;21:1649–54.PubMed
9.
go back to reference Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, Böttger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71:905–13.CrossRefPubMedPubMedCentral Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, Böttger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71:905–13.CrossRefPubMedPubMedCentral
10.
go back to reference Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, Leitch A, Loebinger MR, Milburn HJ, Nightingale M, Ormerod P, Shingadia D, Smith D, Whitehead N, Wilson R, Floto RA. British Thoracic Society guidelines for the diagnosis and management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(Suppl 2):ii1–64.CrossRefPubMed Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, Leitch A, Loebinger MR, Milburn HJ, Nightingale M, Ormerod P, Shingadia D, Smith D, Whitehead N, Wilson R, Floto RA. British Thoracic Society guidelines for the diagnosis and management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(Suppl 2):ii1–64.CrossRefPubMed
11.
go back to reference Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–32.CrossRefPubMedPubMedCentral Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–32.CrossRefPubMedPubMedCentral
12.
go back to reference Jones RB, Tervaert JWC, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Westman K, Jayne DR, European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211–20.CrossRefPubMed Jones RB, Tervaert JWC, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Westman K, Jayne DR, European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211–20.CrossRefPubMed
13.
go back to reference Springer JM, Kermani TA, Sreih A, Shaw DG, Young K, Burroughs CM, Merkel PA. Clinical characteristics of an internet-based cohort of patient-reported diagnosis of granulomatosis with polyangiitis and microscopic polyangiitis: observational study. J Med Internet Res. 2020;22: e17231.CrossRefPubMedPubMedCentral Springer JM, Kermani TA, Sreih A, Shaw DG, Young K, Burroughs CM, Merkel PA. Clinical characteristics of an internet-based cohort of patient-reported diagnosis of granulomatosis with polyangiitis and microscopic polyangiitis: observational study. J Med Internet Res. 2020;22: e17231.CrossRefPubMedPubMedCentral
14.
go back to reference Knight A, Askling J, Granath F, Sparen P, Ekbom A. Urinary bladder cancer in Wegener’s granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis. 2004;63:1307–11.CrossRefPubMedPubMedCentral Knight A, Askling J, Granath F, Sparen P, Ekbom A. Urinary bladder cancer in Wegener’s granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis. 2004;63:1307–11.CrossRefPubMedPubMedCentral
15.
go back to reference Shang W, Ning Y, Xu X, Li M, Guo S, Han M, Zeng R, Ge S, Xu G. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS ONE. 2015;10: e0126016.CrossRefPubMedPubMedCentral Shang W, Ning Y, Xu X, Li M, Guo S, Han M, Zeng R, Ge S, Xu G. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS ONE. 2015;10: e0126016.CrossRefPubMedPubMedCentral
16.
go back to reference Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot MA, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73:1366–83.CrossRefPubMed Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot MA, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73:1366–83.CrossRefPubMed
17.
go back to reference Bruce IN, McAteer JA, Gardiner PV, McFarland RJ, Sloan JM, Bell AL. Chronic suppurative lung disease with associated vasculitis. Postgrad Med J. 1995;71:24–7.CrossRefPubMedPubMedCentral Bruce IN, McAteer JA, Gardiner PV, McFarland RJ, Sloan JM, Bell AL. Chronic suppurative lung disease with associated vasculitis. Postgrad Med J. 1995;71:24–7.CrossRefPubMedPubMedCentral
18.
go back to reference Addy C, Doran G, Jones AL, Wright G, Caskey S, Downey DG. Microscopic polyangiitis secondary to Mycobacterium abscessus in a patient with bronchiectasis: a case report. BMC Pulm Med. 2018;18:170.CrossRefPubMedPubMedCentral Addy C, Doran G, Jones AL, Wright G, Caskey S, Downey DG. Microscopic polyangiitis secondary to Mycobacterium abscessus in a patient with bronchiectasis: a case report. BMC Pulm Med. 2018;18:170.CrossRefPubMedPubMedCentral
19.
go back to reference Wu UI, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. Lancet Infect Dis. 2015;15:968–80.CrossRefPubMed Wu UI, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. Lancet Infect Dis. 2015;15:968–80.CrossRefPubMed
20.
go back to reference Haverkamp MH, van Dissel JT, Holland SM. Human host genetic factors in nontuberculous mycobacterial infection: lessons from single gene disorders affecting innate and adaptive immunity and lessons from molecular defects in interferon-gamma-dependent signaling. Microbes Infect. 2006;8:1157–66.CrossRefPubMed Haverkamp MH, van Dissel JT, Holland SM. Human host genetic factors in nontuberculous mycobacterial infection: lessons from single gene disorders affecting innate and adaptive immunity and lessons from molecular defects in interferon-gamma-dependent signaling. Microbes Infect. 2006;8:1157–66.CrossRefPubMed
21.
go back to reference Asano S, Mizuno S, Okachi S, Aso H, Wakahara K, Hashimoto N, Ito S, Kozaki Y, Katsuno T, Maruyama S, Hasegawa Y. Antineutrophil cytoplasmic antibody-associated vasculitis superimposed on infection-related glomerulonephritis secondary to pulmonary mycobacterium avium complex infection. Intern Med. 2016;55:2439–45.CrossRefPubMed Asano S, Mizuno S, Okachi S, Aso H, Wakahara K, Hashimoto N, Ito S, Kozaki Y, Katsuno T, Maruyama S, Hasegawa Y. Antineutrophil cytoplasmic antibody-associated vasculitis superimposed on infection-related glomerulonephritis secondary to pulmonary mycobacterium avium complex infection. Intern Med. 2016;55:2439–45.CrossRefPubMed
Metadata
Title
The successful treatment of microscopic polyangiitis associated with non-tuberculous mycobacterial-pulmonary disease
Authors
Ryuichi Yoshii
Kengo Kajiwara
Naomichi Uemura
Koki Matsushita
Tomohumi Nakamura
Masao Tomita
Masashi Mukoyama
Publication date
09-12-2023
Publisher
Springer Nature Singapore
Published in
CEN Case Reports
Electronic ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-023-00839-x
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine